Mesalazine

Generic Name: Mesalazine

Brand Names: Apriso, Asacol, Canasa, Delzicol, Lialda, Mezavant, Pentasa, Rowasa, Salofalk, Zaldyon

Drug Type: Small Molecule

Chemical Formula: C_₇H_₇NO_₃

CAS Number: 89-57-6

Unique Ingredient Identifier: 4Q81I59GXC

Background: An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stabil...

Indication: 适用于溃疡性结肠炎和克罗恩病（Crohn病）。

Associated Conditions: Acute Ulcerative Colitis, Crohn's Disease Relapse, Crohn's Ileocolitis, Mild to Moderate Ulcerative Colitis, Proctitis, Proctitis, Ulcerative, Proctosigmoiditis, Ulcerative Colitis in Remission, Mild Ulcerative Colitis, Mild to moderate distal ulcerative colitis, Moderate Ulcerative colitis

Associated Therapies: -

Clinical Trials

Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Delzicol
Drug: IBD98-M without HA

First Posted Date: 2014-07-22

Last Posted Date: 2015-04-22

Lead Sponsor: Holy Stone Healthcare Co., Ltd

Target Recruit Count: 30

Registration Number: NCT02196662

Locations: 🇨🇦
inVentiv Health Clinique, Quebec, Canada

Taste Assessment Study of SHP429 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mesalamine

First Posted Date: 2014-04-29

Last Posted Date: 2021-06-03

Lead Sponsor: Shire

Target Recruit Count: 18

Registration Number: NCT02125292

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Mesalazine

First Posted Date: 2014-03-04

Last Posted Date: 2016-12-02

Lead Sponsor: SOFAR S.p.A.

Target Recruit Count: 21

Registration Number: NCT02077777

Locations: 🇮🇹
Istituti Ospitalieri di Cremona, Cremona, Italy

Mesalazine Effects in Sporadic Colorectal Adenoma Patients

Phase 2

Completed

Conditions: Sporadic Colorectal Adenoma

Interventions: Drug: Mesalazine
Drug: Placebo

First Posted Date: 2013-07-10

Last Posted Date: 2015-12-08

Lead Sponsor: UMC Utrecht

Target Recruit Count: 74

Registration Number: NCT01894685

Locations: 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands

Mesalamine in Environmental Enteropathy

Phase 1

Completed

Conditions: Malnutrition

Interventions: Drug: Placebo granules
Drug: Mesalamine

First Posted Date: 2013-04-26

Last Posted Date: 2014-07-11

Lead Sponsor: Kelsey Jones

Target Recruit Count: 44

Registration Number: NCT01841099

Locations: 🇰🇪
Baraka Clinic, Nairobi, Mathare, Kenya

Evaluation of the Metabolome in Diverticular Disease

Conditions: Simple Diverticular Disease

Interventions: Dietary Supplement: VSL#3
Drug: Rifaximin
Dietary Supplement: Psyllium
Drug: Mesalazine

First Posted Date: 2013-04-15

Last Posted Date: 2014-10-17

Lead Sponsor: S.Eugenio Hospital

Target Recruit Count: 40

Registration Number: NCT01831323

Locations: 🇮🇹
Sant'Eugenio Hospital, Rome, RM, Italy

Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia

Phase 4

Conditions: Intestinal LNH

Interventions: Behavioral: DIET
Drug: Mesalamine

First Posted Date: 2013-02-12

Last Posted Date: 2013-02-12

Lead Sponsor: Azienda Policlinico Umberto I

Target Recruit Count: 270

Registration Number: NCT01789294

Locations: 🇮🇹
Departments of Pediatrics, Sapienza - University of Rome, Rome, Italy

Mesalazine Treatment in IBS (The MIBS Study)

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Mesalazine

First Posted Date: 2012-10-03

Last Posted Date: 2017-02-24

Lead Sponsor: Hans Törnblom

Target Recruit Count: 211

Registration Number: NCT01699438

Locations: 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪
Norrland's University Hospital, Umeå, Sweden
🇸🇪
Karolinska University Hospital, Huddinge, Sweden

Cimzia Versus Mesalamine for Crohn's Recurrence

Phase 4

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Cimzia
Drug: Mesalamine

First Posted Date: 2012-10-02

Last Posted Date: 2018-01-12

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 10

Registration Number: NCT01696942

Locations: 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study

Phase 2

Completed

Conditions: Colonic Diverticulosis

Interventions: Drug: Placebo
Drug: Mesalamine

First Posted Date: 2012-06-25

Last Posted Date: 2016-01-21

Lead Sponsor: Dr. Falk Pharma GmbH

Target Recruit Count: 123

Registration Number: NCT01627262

Locations: 🇩🇪
Ev. Krankenhaus Kalk, University of Cologne, Köln, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy